Rapalogs have also been trialled in prostate cancer, where it was hoped that the high level of PI3K-mTORC1 signalling, often due to PTEN loss, would make these tumours susceptible to mTORC1 inhibition. The gene discussed is PTEN; the disease is prostate cancer.